Education and Training
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
The purpose of this research study is to see if recurrent prostate cancer can be identified using a special procedure called a positron emission tomography (PET) scan. PET/CT is used to describe information regarding the function, as well as location and size of a tumor.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- procedure: Computed Tomography (CT) scan
- drug: 68Ga-PSMA-11
- procedure: Positron Emission Tomography (PET)
Eligibility
Inclusion Criteria:
- Histopathological proven prostate adenocarcinoma
- Rising prostate-specific antigen (PSA) after definitive therapy with prostatectomy or
radiation therapy (external beam or brachytherapy)
- Post radical prostatectomy (RP) - American Urology Association (AUA)
recommendation
- PSA greater than 0.2 ng/mL measured 6 to 13 weeks after RP
- Confirmatory persistent PSA greater than 0.2 ng/mL (total of two PSA
measurements greater than 0.2 ng/mL)
- Post-radiation therapy -American Society for Radiation Oncology (ASTRO)-Phoenix
consensus definition
- A rise of PSA measurement of 2 or more ng/mL over the nadir
- Karnofsky performance status of ≥ 50 (or Eastern Cooperative Oncology Group [ECOG] /
World Health Organization [WHO] equivalent)
- Able to provide written consent
Exclusion Criteria:
- Investigational therapy for prostate cancer.
- Unable to lie flat, still or tolerate a positron emission tomograpy (PET) scan.
- Prior history of any other malignancy within the last 2 years, other than skin basal
cell or cutaneous superficial squamous cell carcinoma that has not metastasized and
superficial bladder cancer.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
Male
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
David Marcellus
650-723-4547
Not Recruiting